Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBT Margin (2016 - 2026)

Collegium Pharmaceutical has reported EBT Margin over the past 10 years, most recently at 14.13% for Q4 2025.

  • For Q4 2025, EBT Margin rose 464.0% year-over-year to 14.13%; the TTM value through Dec 2025 reached 11.87%, down 866.0%, while the annual FY2025 figure was 11.87%, 374.0% down from the prior year.
  • EBT Margin for Q4 2025 was 14.13% at Collegium Pharmaceutical, down from 20.75% in the prior quarter.
  • Over five years, EBT Margin peaked at 195.7% in Q3 2024 and troughed at 435.82% in Q1 2022.
  • A 5-year average of 7.79% and a median of 12.3% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -45346bps in 2022 and later skyrocketed 42369bps in 2023.
  • Year by year, EBT Margin stood at 101.43% in 2021, then surged by 94bps to 6.01% in 2022, then skyrocketed by 619bps to 31.19% in 2023, then crashed by -70bps to 9.49% in 2024, then soared by 49bps to 14.13% in 2025.
  • Business Quant data shows EBT Margin for COLL at 14.13% in Q4 2025, 20.75% in Q3 2025, and 9.06% in Q2 2025.